For Patients Currently Prescribed ADUHELM
Biogen has discontinued the commercialization and sale of ADUHELM. Patients currently prescribed and taking ADUHELM will be eligible for continued dosing until November 1, 2024. ADUHELM will no longer be available for purchase after November 1, 2024.*
*Patient out-of-pocket cost may vary based on financial and other income considerations. This program only covers the cost of ADUHELM. Other services or fees associated with treatment are not included and patients may have out-of-pocket costs associated with the same. Other restrictions apply. Biogen reserves the right to modify or discontinue this program with respect to any patient, or in its entirety, at any time. Patients currently enrolled in the Free Drug program, who are currently enrolled in the PATH program, who have already applied for enrollment in the PATH program, or who purchase ADUHELM outside of these programs will continue to have access through November 1, 2024. Patients' last infusion date must be on or before November 1, 2024, after which ADUHELM will no longer be on the market. After January 31, 2024 no new patient applications were accepted for review in the PATH program. Contact Biogen Support Services for Patients for full program details and Terms and Conditions.
About ADUHELM
ADUHELM attaches to and reduces amyloid plaques, a buildup of proteins in the brains of people with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease.
What are amyloid plaques?
Amyloid plaques are clumps of protein that may:
- Build up in the brain over time
- Begin appearing long before symptoms occur
- Lead to the loss of brain function
Amyloid plaques are a key
feature of Alzheimer’s.
Your doctor will decide if you need further testing to check the levels of amyloid plaques in your brain.
How ADUHELM works
ADUHELM works inside
the brain
Amyloid plaques building
up in
the brain is one
component of
Alzheimer’s.
ADUHELM binds
to amyloid
plaques
in the brain.
Then ADUHELM helps remove
some of the amyloid to reduce
the
amount of plaques in the brain.
These images are for illustrative purposes only. They are not meant to exactly represent the brain or all components that may contribute to the loss of brain function in Alzheimer’s.
ADUHELM is indicated for the treatment of Alzheimer’s disease. ADUHELM should be started in patients with mild cognitive impairment or mild dementia stage of disease, the population studied in clinical trials. ADUHELM is approved under accelerated approval based on reduction in amyloid plaques as seen in patients treated with ADUHELM. Continued approval of ADUHELM may require verification of clinical benefit in a confirmatory study.
How ADUHELM is given
ADUHELM is given:
Through a needle placed in a vein in your arm. This is called an intravenous infusion, or IV
Every 4 weeks. Each infusion takes about one hour. Your doctor will set up a schedule
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
- Especially tell your healthcare provider if you take medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin). Ask your healthcare provider for a list of these medicines if you are not sure
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Registry Information
There is a registry that collects information on treatments for Alzheimer’s disease. The registry is named ALZ-NET (Alzheimer’s Network for Treatment and Diagnostics). Your healthcare provider can help you become enrolled in this registry.
Continue: